LXRX

Lexicon Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website lexpharma.com
Employees(FY) 135
ISIN US5288723027

Performance

-32.15%

-61.18%

-52.22%

-54.38%

-47.23%

YTD

-31.58%

Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Advanced Technical Analysis

Technical Analysis of LXRX 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors, as the prevailing trend appea...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of LXRX

Stock Rank

Recent News & Updates

2024-11-13 19:00
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago(Globenewswire)
2024-11-12 13:20
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...(Yahoo Finance)
2024-11-12 04:25
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates(Yahoo Finance)
2024-11-12 03:25
Lexicon: Q3 Earnings Snapshot(Yahoo Finance)
2024-11-12 03:05
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-11-10 18:15
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For(Yahoo Finance)
2024-11-07 04:02
S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate(Investopedia)
2024-11-05 19:00
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference(Globenewswire)
2024-11-05 13:58
A diabetes drug, twice rejected, stumbles again but its developer persists(Yahoo Finance)
2024-11-05 03:05
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease(Globenewswire)
2024-11-04 19:00
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024(Globenewswire)
2024-11-03 19:00
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss(Yahoo Finance)
2024-10-31 06:54
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease(Globenewswire)
2024-10-27 17:35
FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting(TipRanks)
2024-10-23 09:00
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024(GlobeNewswire)
2024-10-22 21:00
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024(Globenewswire)
2024-10-22 08:00
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)(GlobeNewswire)
2024-10-21 20:00
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)(Globenewswire)
2024-10-17 07:15
Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe(BioPharma Dive)
2024-10-17 05:55
Lexicon partners Viatris for global expansion of sotagliflozin(Pharmaceutical Technology)
2024-10-16 17:53
Lexicon Pharmaceuticals to Get $25 Million From Viatris in Global Sotagliflozin Licensing Deal(MT Newswires)
2024-10-16 16:35
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe(GlobeNewswire)
2024-10-16 16:34
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe(PR Newswire)
2024-10-16 04:35
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe(Globenewswire)
2024-10-16 04:34
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe(Prnewswire)
2024-10-09 15:53
Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...(GuruFocus.com)
2024-09-27 08:00
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress(GlobeNewswire)
2024-09-26 20:00
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress(Globenewswire)
2024-09-16 09:04
Lexicon Pharmaceuticals COO Jeff Wade Steps Down(MT Newswires)
2024-09-16 08:00
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer(GlobeNewswire)

Page 1 of 8

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.